# Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

> **NCT01689155** · — · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 116 (actual)

## Conditions studied

- Meningitis
- Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

## Key facts

- **NCT ID:** NCT01689155
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-06
- **Final completion:** 2016-04
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2016-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689155, "Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01689155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*